Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first precision medicine combo for patients with BRCA2-mutated metasta | Akeega, a ...
GlobalData on MSN
J&J gains label expansion approval for Akeega in mCSPC
Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer treatment landscape ...
Angelina Jolie's long-rumored relocation plans are very much alive and gaining momentum, according to close sources.
HealthDay on MSN
San Antonio Breast Cancer Symposium, Dec. 9 to 12
The annual San Antonio Breast Cancer Symposium was held from Dec. 9 to 12 in San Antonio. Attendees included medical ...
Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...
Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...
Angelina Jolie shows mastectomy scars to spotlight breast health on TIME France. The Oscar-winning actor appears on the first ...
AstraZeneca & Daiichi Sankyo’s Enhertu gets US FDA breakthrough therapy designation in US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
CHARLOTTE, N.C.- Angelina Jolie is getting intimate as she graces the cover of “Time France.” The actress revealed her mastectomy scar, more than a decade after going under the knife. During an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback